News & Updates

First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.

Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.

Women with inflammatory bowel disease (IBD) who use hormonal contraceptives (HCs) appear to be less likely to experience IBD-related symptoms but are more likely to have intestinal inflammation over a year, reports a study.

Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.

In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achiev­ing steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with un­complicated mild-to-moderately active inflammatory bowel disease (IBD).